

# Fibrinolytic parameters in women with heavy menstrual bleeding

No registrations found.

|                              |                            |
|------------------------------|----------------------------|
| <b>Ethical review</b>        | Not applicable             |
| <b>Status</b>                | Pending                    |
| <b>Health condition type</b> | -                          |
| <b>Study type</b>            | Observational non invasive |

## Summary

### ID

NL-OMON22702

### Source

Nationaal Trial Register

### Brief title

Menorrhagia and systemic fibrinolysis

### Health condition

Heavy menstrual bleeding / Hevig menstrueel bloedverlies

Menorrhagia / menorrhagie

Menstrual cycle / menstruele cyclus

Fibrinolysis / fibrinolyse

Clot lysis time / Clot lysis tijd

## Sponsors and support

**Primary sponsor:** University Medical Centre Groningen

Department of Hematology

Prof. J.C. Kluin-Nelemans

Hanzeplein 1

9713 GZ Groningen

**Source(s) of monetary or material Support:** University Medical Centre Groningen

Department of Hematology

Prof. J.C. Kluin-Nelemans

Hanzeplein 1

9713 GZ Groningen

## Intervention

## Outcome measures

### Primary outcome

- Investigate the cyclic variation in clot lysis time in women with HMB in comparison to controls.

### Secondary outcome

- Investigate the cyclic variation in TAFI, PAI-1, tPA, PI, thrombin generation, fibrin clot permeation and confocal microscopy analysis of fibrin clots in women with HMB in comparison to controls.
- Investigate the ovulatory menstrual cycle by measuring progestagen.

## Study description

### Background summary

Heavy menstrual bleeding (HMB) is known to be associated with gynaecological abnormalities and can also be associated with a wide range of haemostatic disorders. There is also evidence that fibrinolysis in the endometrium plays an important role in menstruation. The role of systemic fibrinolysis in women with heavy menstrual bleeding was studied and showed no increased systemic fibrinolysis in women with heavy menstrual bleeding. Certain fibrinolytic parameters were even higher in patients with heavy menstrual bleeding. An explanation why we found no increased systemic fibrinolysis could be the moment of testing in the menstrual cycle. Probably there is cyclic variation in menstruating women with menorrhagia. This hypothesis needs to be tested by measuring fibrinolytic parameters during the menstrual cycle in women with HMB and controls with normal menstrual bleeding.

### Study design

Overview of measurements during the study

- Questionnaire: week 1
- PBAC: week 1
- Blood: Fibrinolytic parameters: week 1,2,3, 4

- Blood: Progesterone: week 3

## **Intervention**

Patients are asked to fill out a questionnaire and to withdraw blood 4 times (one time every week, for 4 weeks in a row).

## **Contacts**

### **Public**

Hanzeplein 1  
S. Wiewel-Verschueren  
Groningen 9713 GZ  
The Netherlands  
050-3610225

### **Scientific**

Hanzeplein 1  
S. Wiewel-Verschueren  
Groningen 9713 GZ  
The Netherlands  
050-3610225

## **Eligibility criteria**

### **Inclusion criteria**

Inclusion criteria for patients:

- Patients with regular heavy menstrual bleeding (=menorrhagia).
- Age over 18 years.
- Written informed consent.

Inclusion criteria for healthy controls with regular menstrual blood loss:

- Age over 18 years.
- Written informed consent.

## Exclusion criteria

Exclusion criteria for patients:

- Patients with postmenopausal, postcoital or intermenstrual bleeding
- Patients with an intra-uterine device or hormonal treatment.
- Patients with anticoagulant, antithrombotic therapy or use of non-steroidal anti-inflammatory drugs (NSAID's).
- Patients with uterine fibroids > 2 cm in diameter.
- Patients with a Body Mass Index >30 kg/m<sup>2</sup>.
- Patients with a Pictorial Bleeding Assessment Chart-score <200.

Exclusion criteria for healthy controls:

- Women with postmenopausal, postcoital or intermenstrual bleeding.
- Women with an intra-uterine device or hormonal treatment.
- Women with anticoagulant, antithrombotic therapy or use of non-steroidal anti-inflammatory drugs (NSAID's).
- Women with a Body Mass Index >30 kg/m<sup>2</sup>.

## Study design

### Design

|                     |                            |
|---------------------|----------------------------|
| Study type:         | Observational non invasive |
| Intervention model: | Other                      |
| Allocation:         | Non controlled trial       |
| Masking:            | Open (masking not used)    |
| Control:            | N/A , unknown              |

### Recruitment

NL

|                           |             |
|---------------------------|-------------|
| Recruitment status:       | Pending     |
| Start date (anticipated): | 01-11-2014  |
| Enrollment:               | 20          |
| Type:                     | Anticipated |

## Ethics review

Not applicable  
Application type: Not applicable

## Study registrations

### Followed up by the following (possibly more current) registration

ID: 42249  
Bron: ToetsingOnline  
Titel:

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

| Register | ID             |
|----------|----------------|
| NTR-new  | NL4671         |
| NTR-old  | NTR4823        |
| CCMO     | NL50151.042.14 |
| OMON     | NL-OMON42249   |

## Study results

### Summary results

Our previous research on this topic is published:<br>

Titel: No increased fibrinolysis in women with heavy menstrual bleeding. <br>

Authors: Wiewel-Verschueren S, Knol HM, Lisman T, Bogchelman DH, Kluin-Nelemans JC, van der Zee AG, Mulder AB, Meijer K.<br>

Published: J Thromb Haemost. 2014 Sep;12(9):1488-93.